Azora Therapeutics AhR agonist (Gastroenterology)

Azora Therapeutics is developing an undisclosed small molecule aryl hydrocarbon receptor (AhR) agonist for a specific, currently unnamed gastroenterology indication. The aryl hydrocarbon receptor is a ligand-activated transcription factor that plays a critical role in maintaining intestinal homeostasis and regulating mucosal immune responses. By activating AhR, the drug is designed to rebalance the body's natural immune mechanisms, which typically involves decreasing T-helper 17 (Th17) activity, increasing T-regulatory (Treg) cell differentiation, and enhancing the physical barrier function of the intestinal epithelium. This asset is part of Azora's broader pipeline of AhR-targeting therapies, which includes the more advanced candidate AT-177 for ulcerative colitis.